Abstract

YKL-40 is a secretory protein secreted among others by tumor cells and tumor-associated macrophages. Due to the structural homology this protein was classified to chitinases family CLP (chitinase – like protein) and to 18 of glycosyl hydrolase family, but it has no catalytic function. Elevated levels of YKL-40 in serum is observed in the inflammatory diseases of various aetiology and in cancers, such as breast, ovarian, colon or lung. The results of many studies suggest a significant relationship of YKL-40 with progression of cancer: incidence of metastases, shorter relapse-free survival and shorter overall survival. It is believed that YKL-40 may be a prognostic factor of cancer development and the patient’s response to the applied therapy. Elevated levels of protein in serum of cancer patients may play a role in angiogenesis, proliferation and migration of tumor cells. Probably the mechanism of this phenomenon is the result of YKL-40 action by FAK and PI3K/AKT signaling pathways. Results obtained so far are largely based on an analysis of the YKL-40 level in the patients’ serum and on the assessment of changes in the expression level of this protein in studies in vitro and in vivo.

References

• 1. Alamanos Y., Drosos A.A.: Epidemiology of adult rheumatoid arthritis.Autoimmun. Rev., 2005; 4: 130-136
  Google Scholar
• 2. Allin K.H., Bojesen S.E., Johansen J.S., Nordestgaard B.G.: Cancerrisk by combined levels of YKL-40 and C-reactive protein in the generalpopulation. Br. J. Cancer, 2012; 106: 199-205
  Google Scholar
• 3. Baeten D., Boots A.M., Steenbakkers P.G., Elewaut D., Bos E., VerheijdenG.F., Berheijden G., Miltenburg A.M., Rijnders A.W., Veys E.M.,De Keyser F.: Human cartilage gp-39+,CD16+ monocytes in peripheralblood and synovium: correlation with joint destruction in rheumatoidarthritis. Arthritis Rheum., 2000; 43: 1233-1243
  Google Scholar
• 4. Bakker M.F., Cavet G., Jacobs J.W., Bijlsma J.W., Haney D.J., Shen Y.,Hesterberg L.K., Smith D.R., Centola M., van Roon J.A., Lafeber F.P.,Welsing P.M.: Performance of a multi-biomarker score measuringrheumatoid arthritis disease activity in the CAMERA tight controlstudy. Ann. Rheum. Dis., 2012; 71: 1692-1697
  Google Scholar
• 5. Belge K.U., Dayyani F., Horelt A., Siedlar M., Frankenberger M.,Frankenberger B., Espevik T., Ziegler-Heitbrock L.: The proinflammatoryCD14+CD16+DR++ monocytes are a major source of TNF. J.Immunol., 2002; 168: 3536-3542
  Google Scholar
• 6. Bergmann O.J., Johansen J.S., Klausen T.W., Mylin A.K., KristensenJ.S., Kjeldsen E., Johnsen H.E.: High serum concentration of YKL-40is associated with short survival in patients with acute myeloid leukemia.Clin. Cancer Res., 2005; 11: 8644-8652
  Google Scholar
• 7. Bjørn M.E., Andersen C.L., Jensen M.K., Hasselbalch H.C.: CirculatingYKL-40 in myelofibrosis a potential novel biomarker of diseaseactivity and the inflammatory state. Eur. J. Haematol., 2014;93: 224-228
  Google Scholar
• 8. Boot R.G., van Achterberg T.A., van Aken B.E., Renkema G.H., JacobsM.J., Aerts J.M., de Vries C.J.: Strong induction of members ofthe chitinase family of proteins in atherosclerosis: chitotriosidaseand human cartilage gp-39 expressed in lesion macrophages. Arterioscler.Thromb. Vasc. Biol., 1999; 19: 687-694
  Google Scholar
• 9. Chen C.C., Pekow J., Llado V., Kanneganti M., Lau C.W., MizoguchiA., Mino-Kenudson M., Bissonnette M., Mizoguchi E.: Chitinase3-like-1 expression in colonic epithelial cells as a potentially novelmarker for colitis-associated neoplasia. Am. J. Pathol., 2011; 179:1494-1503
  Google Scholar
• 10. Chen J.J., Lin Y.C., Yao P.L., Yuan A., Chen H.Y., Shun C.T., TsaiM.F., Chen C.H., Yang P.C.: Tumor-associated macrophages: the double-edgedsword in cancer progression. J. Clin. Oncol., 2005; 23:953-964
  Google Scholar
• 11. Chudecka-Głaz A.M., Cymbaluk-Płoska A.A., Menkiszak J.L., Sompolska-RzechułaA.M., Tołoczko-Grabarek A.I., Rzepka-Górska I.A.:Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimaldebulking surgery, response to chemotherapy in ovarian cancer. J.Ovarian Res., 2014; 7: 62
  Google Scholar
• 12. Cintin C., Johansen J.S., Christensen I.J., Price P.A., Sørensen S.,Nielsen H.J.: High serum YKL-40 level after surgery for colorectalcarcinoma is related to short survival. Cancer, 2002; 95: 267-274
  Google Scholar
• 13. Cintin C., Johansen J.S., Christensen I.J., Price P.A., SørensenS., Nielsen H.J.: Serum YKL-40 and colorectal cancer. Br. J. Cancer,1999; 79: 1494-1499
  Google Scholar
• 14. Coenen M.J., Gregersen P.K.: Rheumatoid arthritis: a view of thecurrent genetic landscape. Genes Immun., 2009; 10: 101-111
  Google Scholar
• 15. Coussens L.M., Werb Z.: Inflammation and cancer. Nature, 2002;420: 860-867
  Google Scholar
• 16. Dehn H., Høgdall E.V., Johansen J.S., Jørgensen M., Price P.A.,Engelholm S.A., Høgdall C.K.: Plasma YKL-40, as a prognostic tumormarker in recurrent ovarian cancer. Acta Obstet. Gynecol. Scand.,2003; 82: 287-293
  Google Scholar
• 17. Demaria S., Pikarsky E., Karin M., Coussens L.M., Chen Y.C., El–Omar E.M., Trinchieri G., Dubinett S.M., Mao J.T., Szabo E., Krieg A.,Weiner G.J., Fox B.A., Coukos G., Wang E. i wsp.: Cancer and inflammation:promise for biologic therapy. J. Immunother., 2010; 33: 335-351
  Google Scholar
• 18. Díaz-Lagares A., Alegre E., Arroyo A., González-Cao M., ZudaireM.E., Viteri S., Martín-Algarra S., González A.: Evaluation of multipleserum markers in advanced melanoma. Tumour Biol., 2011;32: 1155-1161
  Google Scholar
• 19. Diefenbach C.S., Shah Z., Iasonos A., Barakat R.R., Levine D.A.,Aghajanian C., Sabbatini P., Hensley M.L., Konner J., Tew W., SpriggsD., Fleisher M., Thaler H., Dupont J.: Preoperative serum YKL-40 isa marker for detection and prognosis of endometrial cancer. Gynecol.Oncol., 2007; 104: 435-442
  Google Scholar
• 20. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W.: Monocyte/macrophageinfiltration in tumors: modulators of angiogenesis.J. Leukoc. Biol., 2006; 80: 1183-1196
  Google Scholar
• 21. Dupont J., Tanwar M.K., Thaler H.T., Fleisher M., Kauff N., HensleyM.L., Sabbatini P., Anderson S., Aghajanian C., Holland E.C.,Spriggs D.R..: Early detection and prognosis of ovarian cancer usingserum YKL-40. J. Clin. Oncol., 2004; 22: 3330-3339
  Google Scholar
• 22. Egberts F., Kotthoff E.M., Gerdes S., Egberts J.H., Weichenthal M.,Hauschild A.: Comparative study of YKL-40, S-100B and LDH as monitoringtools for Stage IV melanoma. Eur. J. Cancer, 2012; 48: 695-702
  Google Scholar
• 23. Faibish M., Francescone R., Bentley B., Yan W., Shao R.: A YKL–40-neutralizing antibody blocks tumor angiogenesis and progression:a potential therapeutic agent in cancers. Mol. Cancer Ther.,2011; 10: 742-751
  Google Scholar
• 24. Francescone R., Ngernyuang N., Yan W., Bentley B., Shao R.:Tumor-derived mural-like cells coordinate with endothelial cells:role of YKL-40 in mural cell-mediated angiogenesis. Oncogene, 2014;33: 2110-2122
  Google Scholar
• 25. Francescone R.A., Scully S., Faibish M., Taylor S.L., Oh D., MoralL., Yan W., Bentley B., Shao R.: Role of YKL-40 in the angiogenesis,radioresistance, and progression of glioblastoma. J. Biol. Chem.,2011; 286: 15332-15343
  Google Scholar
• 26. Frohman T.C., Castro W., Shah A., Courtney A., Ortstadt J., DavisS.L., Logan D., Abraham T., Abraham J., Remington G., TreadawayK., Graves D., Hart J., Stuve O., Lemack G., Greenberg B., FrohmanE.M.: Symptomatic therapy in multiple sclerosis. Ther. Adv. Neurol.Disord., 2011; 4: 83-98
  Google Scholar
• 27. Fusetti F., Pijning T., Kalk K.H., Bos E., Dijkstra B.W.: Crystal structureand carbohydrate-binding properties of the human cartilageglycoprotein-39. J. Biol. Chem., 2003; 278: 37753-37760
  Google Scholar
• 28. Gronlund B., Høgdall E.V., Christensen I.J., Johansen J.S.,Nørgaard-Pedersen B., Engelholm S.A., Høgdall C.: Pre-treatmentprediction of chemoresistance in second-line chemotherapy of ovariancarcinoma: value of serological tumor marker determination(tetranectin, YKL-40, CASA, CA 125). Int. J. Biol. Markers, 2006; 21:141-148
  Google Scholar
• 29. Hakala B.E., White C., Recklies A.D.: Human cartilage gp-39,a major secretory product of articular chondrocytes and synovialcells, is a mammalian member of a chitinase protein family. J. Biol.Chem., 1993; 268: 25803-25810
  Google Scholar
• 30. Hansen M., Nielsen A.R., Vilsbøll T., Lund A., Krarup T., KnopF.K., Vestergaard H.: Increased levels of YKL-40 and interleukin 6 inpatients with chronic pancreatitis and secondary diabetes. Pancreas,2012; 41: 1316-1318
  Google Scholar
• 31. Hashimoto S., Suzuki T., Dong H.Y., Yamazaki N., MatsushimaK.: Serial analysis of gene expression in human monocytes and macrophages.Blood, 1999; 94: 837-844
  Google Scholar
• 32. He C.H., Lee C.G., Dela Cruz C.S., Lee C.M., Zhou Y., AhangariF., Ma B., Herzog E.L., Rosenberg S.A., Li Y., Nour A.M., Parikh C.R.,Schmidt I., Modis Y., Cantley L., Elias J.A.: Chitinase 3-like 1 regulatescellular and tissue responses via IL-13 receptor α2. Cell Rep.,2013; 4: 830-841
  Google Scholar
• 33. Høgdall E.V., Ringsholt M., Høgdall C.K., Christensen I.J., JohansenJ.S., Kjaer S.K., Blaakaer J., Ostenfeld-Møller L., Price P.A., ChristensenL.H.: YKL-40 tissue expression and plasma levels in patientswith ovarian cancer. BMC Cancer, 2009; 9: 8
  Google Scholar
• 34. Horbinski C., Wang G., Wiley C.A.: YKL-40 is directly producedby tumor cells and is inversely linked to EGFR in glioblastomas. Int.J. Clin. Exp. Pathol., 2010; 3: 226-237
  Google Scholar
• 35. Iwamoto F.M., Hormigo A.: Unveiling YKL-40, from serum markerto target therapy in glioblastoma. Front. Oncol., 2014; 4: 90
  Google Scholar
• 36. Jensen B.V., Johansen J.S., Price P.A.: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastaticbreast cancer. Clin. Cancer Res., 2003; 9: 4423-4434
  Google Scholar
• 37. Jensen P., Wiell C., Milting K., Poggenborg R.P., Østergaard M.,Johansen J.S., Skov L.: Plasma YKL-40: a potential biomarker for psoriaticarthritis? J. Eur. Acad. Dermatol. Venereol., 2013; 27: 815-819
  Google Scholar
• 38. Johansen J.S.: Studies on serum YKL-40 as a biomarker in diseaseswith inflammation, tissue remodelling, fibroses and cancer.Dan. Med. Bull., 2006; 53: 172-209
  Google Scholar
• 39. Johansen J.S., Christensen I.J., Riisbro R., Greenall M., Han C.,Price P.A., Smith K., Brünner N., Harris A.L.: High serum YKL-40 levelsin patients with primary breast cancer is related to short recurrencefree survival. Breast Cancer Res. Treat., 2003; 80: 15-21 40 Johansen J.S., Christoffersen P., Møller S., Price P.A., HenriksenJ.H., Garbarsch C., Bendtsen F.: Serum YKL-40 is increased in patientswith hepatic fibrosis. J. Hepatol., 2000; 32: 911-920
  Google Scholar
• 40. protein expression in the early developing human musculoskeletalsystem. J. Histochem. Cytochem., 2007; 55: 1213-1228
  Google Scholar
• 41. Johansen J.S., Drivsholm L, Price P.A., Christensen I.J.: High serumYKL-40 level in patients with small cell lung cancer is relatedto early death. Lung Cancer, 2004; 46: 333-340
  Google Scholar
• 42. Johansen J.S., Høyer P.E., Larsen L.A., Price P.A., Møllgård K.: YKL-
  Google Scholar
• 43. Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A.: SerumYKL-40, a new prognostic biomarker in cancer patients? CancerEpidemiol. Biomarkers Prev., 2006; 15: 194-202
  Google Scholar
• 44. Johansen J.S., Jensen B.V., Roslind A., Price P.A.: Is YKL-40 a newtherapeutic target in cancer? Expert Opin. Ther. Targets, 2007; 11:219-234
  Google Scholar
• 45. Johansen J.S., Lottenburger T., Nielsen H.J., Jensen J.E., SvendsenM.N., Kollerup G., Christensen I.J.: Diurnal, weekly, and long-timevariation in serum concentrations of YKL-40 in healthy subjects.Cancer Epidemiol. Biomarkers Prev., 2008; 17: 2603-2608
  Google Scholar
• 46. Johansen J.S., Milman N., Hansen M., Garbarsch C., Price P.A.,Graudal N.: Increased serum YKL-40 in patients with pulmonarysarcoidosis – a potential marker of disease activity? Respir. Med.,2005; 99: 396-402
  Google Scholar
• 47. Johansen J.S., Williamson M.K., Rice J.S., Price P.A.: Identificationof proteins secreted by human osteoblastic cells in culture. J. BoneMiner. Res., 1992; 7: 501-512
  Google Scholar
• 48. Junker N., Johansen J.S., Andersen C.B., Kristjansen P.E.: Expressionof YKL-40 by peritumoral macrophages in human small cell lungcancer. Lung Cancer, 2005; 48: 223-231
  Google Scholar
• 49. Junker N., Johansen J.S., Hansen L.T., Lund E.L., Kristjansen P.E.:Regulation of YKL-40 expression during genotoxic or microenvironmentalstress in human glioblastoma cells. Cancer Sci., 2005;96: 183-190
  Google Scholar
• 50. Kang E.J., Jung H., Woo O.H., Park K.H., Woo S.U., Yang D.S., KimA.R., Lee J.B., Kim Y.H., Kim J.S., Seo J.H.: YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. TumourBiol., 2014; 35: 277-286
  Google Scholar
• 51. Kawada M., Seno H., Kanda K., Nakanishi Y., Akitake R., KomekadoH., Kawada K., Sakai Y., Mizoguchi E., Chiba T.: Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectalcancer. Oncogene, 2012; 31: 3111-3123
  Google Scholar
• 52. Kazakova M., Batalov A., Deneva T., Mateva N., Kolarov Z., SarafianV.: Relationship between sonographic parameters and YKL-40levels in rheumatoid arthritis. Rheumatol. Int., 2013; 33: 341-346
  Google Scholar
• 53. Kim S.H., Das K., Noreen S., Coffman F., Hameed M.: Prognosticimplications of immunohistochemically detected YKL-40 expressionin breast cancer. World J. Surg. Oncol., 2007; 5: 17
  Google Scholar
• 54. Knudsen L.S., Klarlund M., Skjødt H., Jensen T., Ostergaard M.,Jensen K.E., Hansen M.S., Hetland M.L., Nielsen H.J., Johansen J.S.:Biomarkers of inflammation in patients with unclassified polyarthritisand early rheumatoid arthritis. Relationship to disease activityand radiographic outcome. J. Rheumatol., 2008; 35: 1277-1287
  Google Scholar
• 55. Kucur M., Isman F.K., Balci C., Onal B., Hacibekiroglu M., OzkanF., Ozkan A.: Serum YKL-40 levels and chitotriosidase activity as potentialbiomarkers in primary prostate cancer and benign prostatichyperplasia. Urol. Oncol., 2008; 26: 47-52
  Google Scholar
• 56. Kzhyshkowska J., Gratchev A., Goerdt S.: Human chitinases andchitinase-like proteins as indicators for inflammation and cancer.Biomark. Insights, 2007; 2: 128-146
  Google Scholar
• 57. Kzhyshkowska J., Gratchev A., Goerdt S.: Stabilin-1, a homeostaticscavenger receptor with multiple functions. J. Cell. Mol. Med.,2006; 10: 635-649
  Google Scholar
• 58. Lau S.H., Sham J.S., Xie D., Tzang C.H., Tang D., Ma N., Hu L.,Wang Y., Wen J.M., Xiao G., Zhang W.M., Lau G.K., Yang M., GuanX.Y.: Clusterin plays an important role in hepatocellular carcinomametastasis. Oncogene, 2006; 25: 1242-1250
  Google Scholar
• 59. Liu X., Zhang Y., Zhu Z., Ha M., Wang Y.: Elevated pretreatmentserum concentration of YKL-40: an independent prognostic biomarkerfor poor survival in patients with colorectal cancer. Med.Oncol., 2014; 31: 85
  Google Scholar
• 60. Maeda H., Akaike T.: Nitric oxide and oxygen radicals in infection,inflammation, and cancer. Biochemistry, 1998; 63: 854-865
  Google Scholar
• 61. Malmeström C., Axelsson M., Lycke J., Zetterberg H., Blennow K.,Olsson B.: CSF levels of YKL-40 are increased in MS and replaces withimmunosuppressive treatment. J. Neuroimmunol., 2014; 269: 87-89
  Google Scholar
• 62. Mohanty A.K., Singh G., Paramasivam M., Saravanan K., JabeenT., Sharma S., Yadav S., Kaur P., Kumar P., Srinivasan A., SinghT.P.: Crystal structure of a novel regulatory 40-kDa mammary glandprotein (MGP-40) secreted during involution. J. Biol. Chem., 2003;278: 14451-14460
  Google Scholar
• 63. Morrow D.A., de Lemos J.A.: Benchmarks for the assessmentof novel cardiovascular biomarkers. Circulation, 2007; 115: 949-952
  Google Scholar
• 64. Moss S.F., Blaser M.J.: Mechanisms of disease: Inflammation andthe origins of cancer. Nat. Clin. Pract. Oncol., 2005; 2: 90-97
  Google Scholar
• 65. Nazimek K., Bryniarski K.: The biological activity of macrophagesin health and disease. Postępy Hig. Med. Dośw., 2012; 66: 507-520
  Google Scholar
• 66. Nielsen A.R., Erikstrup C., Johansen J.S., Fischer C.P., PlomgaardP., Krogh-Madsen R., Taudorf S., Lindegaard B., Pedersen B.K.:Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes,2008; 57: 3078-3082
  Google Scholar
• 67. Nigro J.M., Misra A., Zhang L., Smirnov I., Colman H., GriffinC., Ozburn N., Chen M., Pan E., Koul D., Yung W.K., Feuerstein B.G.,Aldape K.D.: Integrated array-comparative genomic hybridizationand expression array profiles identify clinically relevant molecularsubtypes of glioblastoma. Cancer Res., 2005; 65: 1678-1686
  Google Scholar
• 68. Nishikawa K.C., Millis A.J.: gp38k (CHI3L1) is a novel adhesionand migration factor for vascular cells. Exp. Cell Res., 2003; 287: 79-87
  Google Scholar
• 69. Nøjgaard C., Johansen J.S., Christensen E., Skovgaard L.T., PriceP.A., Becker U., EMALD Group: Serum levels of YKL-40 and PIIINP asprognostic markers in patients with alcoholic liver disease. J. Hepatol.,2003; 39: 179-186
  Google Scholar
• 70. Nøjgaard C., Johansen J.S., Krarup H.B., Holten-Andersen M.,Møller A., Bendtsen F., Danish Viral Hepatitis Study Group: Effect ofantiviral therapy on markers of fibrogenesis in patients with chronichepatitis C. Scand. J. Gastroenterol., 2003; 38: 659-665
  Google Scholar
• 71. Nutt C.L., Betensky R.A., Brower M.A., Batchelor T.T., Louis D.N.,Stemmer-Rachamimov A.O.: YKL-40 is a differential diagnostic markerfor histologic subtypes of high-grade gliomas. Clin. Cancer Res.,2005; 11: 2258-2264
  Google Scholar
• 72. Ontaneda D., Hyland M., Cohen J.A.: Multiple sclerosis: newinsights in pathogenesis and novel therapeutics. Annu. Rev. Med.,2012; 63: 389-404
  Google Scholar
• 73. Prakash M., Bodas M., Prakash D., Nawani N., Khetmalas M.,Mandal A., Eriksson C.: Diverse pathological implications of YKL-40: answers may lie in ‚outside-in’ signaling. Cell. Signal., 2013; 25:1567-1573
  Google Scholar
• 74. RCSB PDB Protein Data Bank. http://rcsb.org/pdb/explore/explore.do?structureId=1NWR (11.12.2016)
  Google Scholar
• 75. Recklies A.D., Ling H., White C., Bernier S.M.: Inflammatory cytokinesinduce production of CHI3L1 by articular chondrocytes. J.Biol. Chem., 2005; 280: 41213-41221
  Google Scholar
• 76. Recklies A.D., White C., Ling H.: The chitinase 3-like proteinhuman cartilage glycoprotein 39 (HC-gp39) stimulates proliferationof human connective-tissue cells and activates both extracellularsignal-regulated kinase – and protein kinase B-mediated signallingpathways. Biochem. J., 2002; 365: 119-126
  Google Scholar
• 77. Rehli M., Krause S.W., Andreesen R.: Molecular characterizationof the gene for human cartilage gp-39 (CHI3L1), a member of thechitinase protein family and marker for late stages of macrophagedifferentiation. Genomics, 1997; 43: 221-225
  Google Scholar
• 78. Rehli M., Niller H.H., Ammon C., Langmann S., SchwarzfischerL., Andreesen R., Krause S.W.: Transcriptional regulation of CHI3L1,a marker gene for late stages of macrophage differentiation. J. Biol.Chem., 2003; 278: 44058-44067
  Google Scholar
• 79. Renkema G.H., Boot R.G., Au F.L., Donker-Koopman W.E., StrijlandA., Muijsers A.O., Hrebicek M., Aerts J.M.: Chitotriosidase, a chitinase,and the 39-kDa human cartilage glycoprotein, a chitin-bindinglectin, are homologues of family 18 glycosyl hydrolases secretedby human macrophages. Eur. J. Biochem., 1998; 251: 504-509
  Google Scholar
• 80. Riabov V., Gudima A., Wang N., Mickley A., Orekhov A., KzhyshkowskaJ.: Role of tumor associated macrophages in tumor angiogenesisand lymphangiogenesis. Front. Physiol., 2014; 5: 75
  Google Scholar
• 81. Roslind A., Johansen J.S.: YKL-40: a novel marker shared bychronic inflammation and oncogenic transformation. Methods Mol.Biol., 2009; 511: 159-184
  Google Scholar
• 82. Roslind A., Johansen J.S., Junker N., Nielsen D.L., Dzaferi H., PriceP.A., Balslev E.: YKL-40 expression in benign and malignant lesionsof the breast: a methodologic study. Appl. Immunohistochem. Mol.Morphol., 2007; 15: 371-381
  Google Scholar
• 83. Roslind A., Knoop A.S., Jensen M.B., Johansen J.S., Nielsen D.L.,Price P.A., Balslev E.: YKL-40 protein expression is not a prognosticmarker in patients with primary breast cancer. Breast Cancer Res.Treat., 2008; 112: 275-285
  Google Scholar
• 84. Saba M., Sharif M.R., Akbari H., Nikoueinejad H., Ramazani JolfaiiM.: YKL-40 in Asthma and its correlation with different clinicalparameters. Iran. J. Allergy Asthma Immunol., 2014; 13: 271-277
  Google Scholar
• 85. Saidi A., Javerzat S., Bellahcène A., De Vos J., Bello L., CastronovoV., Deprez M., Loiseau H., Bikfalvi A., Hagedorn M.: Experimentalanti-angiogenesis causes upregulation of genes associated withpoor survival in glioblastoma. Int. J. Cancer, 2008; 122: 2187-2198
  Google Scholar
• 86. Salamon J., Hoffmann T., Elies E., Peldschus K., Johansen J.S.,Lüers G., Schumacher U., Wicklein D.: Antibody directed againsthuman YKL-40 increases tumor volume in a human melanoma xenograftmodel in scid mice. PLoS One, 2014; 9: e95822
  Google Scholar
• 87. Salvatore V., Teti G., Bolzani S., Focaroli S., Durante S., MazzottiM.C., Falconi M.: Simulating tumor microenvironment: changesin protein expression in an in vitro co-culture system. Cancer CellInt., 2014; 14: 40
  Google Scholar
• 88. Schmidt H., Johansen J.S., Gehl J., Geertsen P.F., Fode K., von derMaase H.: Elevated serum level of YKL-40 is an independent prognosticfactor for poor survival in patients with metastatic melanoma.Cancer, 2006; 106: 1130-1139
  Google Scholar
• 89. Schmidt H., Johansen J.S., Sjoegren P., Christensen I.J., SorensenB.S., Fode K., Larsen J., von der Maase H.: Serum YKL-40 predictsrelapse-free and overall survival in patients with AmericanJoint Committee on Cancer stage I and II melanoma. J. Clin. Oncol.,2006; 24: 798-804
  Google Scholar
• 90. Schultz N.A., Christensen I.J., Werner J., Giese N., Jensen B.V.,Larsen O., Bjerregaard J.K., Pfeiffer P., Calatayud D., Nielsen S.E.,Yilmaz M.K., Holländer N.H., Wøjdemann M., Bojesen S.E., NielsenK.R., Johansen J.S.: Diagnostic and prognostic impact of circulatingYKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoSOne, 2013; 8: e67059
  Google Scholar
• 91. Schultz N.A., Johansen J.S.: YKL-40-A protein in the field oftranslational medicine: a role as a biomarker in cancer patients?Cancers, 2010; 2: 1453-1491
  Google Scholar
• 92. Scully S., Yan W., Bentley B., Cao Q.J., Shao R.: Inhibitory activityof YKL-40 in mammary epithelial cell differentiation and polarizationinduced by lactogenic hormones: a role in mammary tissueinvolution. PLoS One, 2011; 6: e25819
  Google Scholar
• 93. Shackel N.A., McGuinness P.H., Abbott C.A., Gorrell M.D., McCaughanG.W.: Novel differential gene expression in human cirrhosisdetected by suppression subtractive hybridization. Hepatology,2003; 38: 577-588
  Google Scholar
• 94. Shao R.: YKL-40 acts as an angiogenic factor to promote tumorangiogenesis. Front. Physiol., 2013; 4: 122
  Google Scholar
• 95. Shao R., Cao Q.J., Arenas R.B., Bigelow C., Bentley B., Yan W.:Breast cancer expression of YKL-40 correlates with tumour grade,poor differentiation, and other cancer markers. Br. J. Cancer, 2011;105: 1203-1209
  Google Scholar
• 96. Shao R., Francescone R., Ngernyuang N., Bentley B., Taylor S.L.,Moral L., Yan W.: Anti-YKL-40 antibody and ionizing irradiation synergisticallyinhibit tumor vascularization and malignancy in glioblastoma.Carcinogenesis, 2014; 35: 373-382
  Google Scholar
• 97. Shao R., Hamel K., Petersen L., Cao Q.J., Arenas R.B., Bigelow C.,Bentley B., Yan W.: YKL-40, a secreted glycoprotein, promotes tumorangiogenesis. Oncogene, 2009; 28: 4456-4468
  Google Scholar
• 98. Tarpgaard L.S., Guren T.K., Glimelius B., Christensen I.J., PfeifferP., Kure E.H., Sorbye H., Ikdahl T., Yilmaz M., Johansen J.S., Tveit K.M.:Plasma YKL-40 in patients with metastatic colorectal cancer treatedwith first line oxaliplatin-based regimen with or without cetuximab:results from the NORDIC VII Study. PLoS One, 2014; 9: e87746
  Google Scholar
• 99. Thöm I., Andritzky B., Schuch G., Burkholder I., Edler L., JohansenJ.S., Bokemeyer C., Schumacher U., Laack E.: Elevated pretreatmentserum concentration of YKL-40-An independent prognosticbiomarker for poor survival in patients with metastatic nonsmallcell lung cancer. Cancer, 2010; 116: 4114-4121
  Google Scholar
• 100. Tobón G.J., Youinou P., Saraux A.: The environment, geo-epidemiology,and autoimmune disease: Rheumatoid arthritis. J. Autoimmun.,2010; 35: 10-14
  Google Scholar
• 101. Tuten A., Kucur M., Imamoglu M., Oncul M., Acikgoz A.S., SofiyevaN., Ozturk Z., Kaya B., Oral E.: Serum YKL-40 levels are alteredin endometriosis. Gynecol. Endocrinol., 2014; 30: 381-384
  Google Scholar
• 102. Volck B., Johansen J.S., Stoltenberg M., Garbarsch C., Price P.A.,Ostergaard M., Ostergaard K., Løvgreen-Nielsen P., Sonne-Holm S.,Lorenzen I.: Studies on YKL-40 in knee joints of patients with rheumatoidarthritis and osteoarthritis. Involvement of YKL-40 in thejoint pathology. Osteoarthritis Cartilage, 2001; 9: 203-214
  Google Scholar
• 103. Wang D., Zhai B., Hu F., Liu C., Zhao J., Xu J.: High YKL-40 serumconcentration is correlated with prognosis of Chinese patients withbreast cancer. PLoS One, 2012; 7: e51127
  Google Scholar
• 104. Wang Y., Ripa R.S., Johansen J.S., Gabrielsen A., SteinbruchelD.A., Friis T., Bindslev L., Haack-Sørensen M., Jørgensen E., KastrupJ.: YKL-40 a new biomarker in patients with acute coronary syndromeor stable coronary artery disease. Scand. Cardiovasc. J., 2008;42: 295-302
  Google Scholar
• 105. Xu C.H., Yu L.K., Hao K.K.: Serum YKL-40 level is associatedwith the chemotherapy response and prognosis of patients withsmall cell lung cancer. PLoS One, 2014; 9: e96384
  Google Scholar
• 106. Yamac D., Ozturk B., Coskun U., Tekin E., Sancak B., Yildiz R.,Atalay C.: Serum YKL-40 levels as a prognostic factor in patientswith locally advanced breast cancer. Adv. Ther., 2008; 25: 801-809
  Google Scholar
• 107. Yang G.F., Cai P.Y., Li X.M., Deng H.X., He W.P., Xie D.: Expressionand clinical significance of YKL-40 protein in epithelial ovariancancer tissues. Ai Zheng, 2009; 28: 142-145
  Google Scholar
• 108. Ye H.M., Lu Y.Z., Liang X.M., Lin Y.Z., Li Y., Zhang Z.Y., TzengC.M.: Clinical significance of combined testing of YKL-40 with CEAin Chinese colorectal cancer patients. Clin. Lab., 2014; 60: 397-405
  Google Scholar
• 109. Yip P., Chen T.H., Seshaiah P., Stephen L.L., Michael-Ballard K.L.,Mapes J.P., Mansfield B.C., Bertenshaw G.P.: Comprehensive serumprofiling for the discovery of epithelial ovarian cancer biomarkers.PLoS One, 2011; 6: e29533
  Google Scholar

Full text